|
|
|
| Effect of Yiligan Capsules combined with Tenofovir on liver function and liver fibrosis in patients with hepatitis B cirrhosis |
| WANG Jiebing TANG Pingyang XU Huixuan |
| Department of Hepatology, Cangzhou Infectious Disease Hospital, Hebei Province, Cangzhou 061000, China |
|
|
|
Abstract Objective To explore the effect of Yiligan Capsules combined with Tenofovir on liver function and liver fibrosis in patients with hepatitis B cirrhosis. Methods Ninety patients from May 2015 to March 2018 in Cangzhou Infectious Disease Hospital of Hebei Province were selected and divided into control group and observation group according to random number table method, 45 cases in each group. Control group was treated with Tenofovir, and observation group was given Yiligan Capsules combined with Tenofovir. Clinical efficacy and laboratory examination indexes of two groups were compared. Results Total clinical effective rate of observation group was higher than that of control group (P < 0.05). After treatment, serum total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels of two groups were lower than those before treatment, prothrombin time (PT) of two groups was shorter than that before treatment, and the levels of TBil, ALT and AST in observation group were lower than those in control group, and PT in observation group was shorter than that in control group (P < 0.05). After treatment, the levels of hyaluronidase, blood laminin, type Ⅳ collagen and type Ⅲ procollagen in two groups were lower than those before treatment, and those in observation group were lower than those in control group (P < 0.05). The negative conversion rate of HBV-DNA in observation group was higher than that in control group at 23 and 46 weeks of treatment, and the differences were statistically significant (P < 0.05). Conclusion Yiligan Capsules combined with Tenofovir has significant clinical effect on patients with hepatitis B cirrhosis, it can protect the activity of liver cells, significantly improve the liver function, reduce liver fibrosis and improve the quality of life of patients, which is worthy of clinical application.
|
|
|
|
|
|
[1] 余斌斌.失代偿期肝硬化患者发生医院感染的危险因素[J].山西医药杂志，2018，47（7）：102-104.
[2] 蒋蒙，刘亚允，梁雪松.调节性B细胞与乙型肝炎慢性化研究进展[J].肝脏，2019，24（1）：95-97.
[3] 白萧萧，东冰，徐光华.慢性HBV感染免疫控制期与免疫逃逸期研究进展[J].肝脏，2018，23（4）：344-347.
[4] 黄盛新，黎伟，李雪花，等.猛老虎汤治疗乙肝肝硬化临床疗效及安全性观察[J].辽宁中医杂志，2019，46（6）：1212-1215.
[5] 覃婕.健脾疏肝法治疗乙肝肝硬化代偿期肝郁脾虚证临床观察[J].山西中医，2019，35（5）：26-27.
[6] 张思容.补肾健脾方联合长效干扰素治疗HBeAg阳性慢乙肝的临床研究[D].广州：广州中医药大学，2017.
[7] 李静，杨雅娟，冯艳，等.牛磺酸对实验性肝纤维化大鼠保护作用的研究[J].天津中医药，2017，34（5）：336-340.
[8] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].中华实验和临床感染病杂志：电子版，2015，19（5）：1-18．
[9] 吴眉，徐列明.扶正化瘀胶囊对抗病毒有效的乙型肝炎肝硬化患者外周血细胞因子的调节[J].肝脏，2017，22（12）：1094-1097．
[10] 张凤朝，李沧友，王淑芹，等.蚁利肝治疗慢性乙型肝炎疗效观察[J].中国中医药科技，2001，8（1）：51.
[11] 朱武，刘玉泉，谢万华，等.多项指标联合检测对乙型肝炎后肝硬化诊断治疗中的观察分析[J].检验医学与临床，2013，10（7）：819-820，823.
[12] 马葵芬，张相宜，齐罗扬，等.三萜类化合物对化学损伤原代培养大鼠肝细胞的保护作用[J].浙江大学学报：医学版，2007，36（3）：247-254.
[13] 沈思.茯苓皮中三萜的提取、分离纯化及其活性研究[D].武汉：华中农业大学，2008.
[14] 武守国，高婷婷.益气健脾方联合恩替卡韦对慢性乙型肝炎后肝硬化患者治疗作用的临床观察[J].中国中西医结合消化杂志，2015，23（3）：173-175.
[15] 储成俭，潘一先，钱静.补血活血方对慢性乙型肝炎患者肝功能和肝纤维化的影响[J].上海中医药杂志，2016，50（4）：41-43.
[16] 熊莎，高建蓉，胡祖良，等.鳖甲提取物对抑制TGF-β诱导的大鼠肝星状细胞活化的影响[J].中国实验方剂学杂志，2017，23（19）：155-159.
[17] 李静，刘艳丽，李同进.中成药治疗慢性乙型肝炎肝纤维化疗效观察[J].中国临床医生杂志，2015，43（2）：59-60.
[18] 刘鸣昊，王胜超，张丽慧，等.近10年脂肪肝的中医证治用药规律分析[J].中华中医药学刊，2016，34（12）：2852-2855.
[19] 肖伟.扶正化瘀胶囊联合恩替卡韦治疗失代偿期乙肝肝硬化的效果分析[J].山西职工医学院学报，2019（3）：79-81.
[20] 杨志勇，吴晓枫，张明香，等.抗病毒药物治疗对失代偿期乙型肝炎肝硬化患者长期预后的影响[J].中国现代医生，2018，56（19）：75-77，81.
[21] 吴红红，胡敏华.干预专案对乙肝病毒感染肝硬化患者自我管理能力的影响[J].中国现代医生，2019，57（15）：140-142.
[22] 丁青，陈冻伢.莫沙必利对乙型肝炎肝硬化代偿期肠道微生态的影响[J].中国现代医生，2019，57（23）：44-47.
[23] 丁大勇，马舒伟.蚂蚁成分及药理研究的进展[J].黑龙江医药，2005，18（5）：330-331. |
|
|
|
